AbCellera Biologics Inc. (ABCL)

Market Cap	1.22B +83.8%
Revenue (ttm)	75.13M +160.6%
Net Income	-146.41M
EPS	-0.49
Shares Out	303.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,808,595
Open	3.910
Previous Close	3.830
Day's Range	3.870 - 4.050
52-Week Range	1.940 - 6.515
Beta	0.85
Analysts	Strong Buy
Price Target	8.40 (+109.48%)
Earnings Date	May 11, 2026

About ABCL

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lil...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 562
• Stock Exchange: NASDAQ
• Ticker Symbol: ABCL
• Website: https://www.abcellera.com

Financial Performance

In 2025, AbCellera Biologics's revenue was $75.13 million, an increase of 160.56% compared to the previous year's $28.83 million. Losses were -$146.41 million, -10.10% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price target is $8.4, which is an increase of 109.48% from the latest price.

Price Target

$8.4

(109.48% upside)

Analyst Consensus: Strong Buy